Joseph Kim serves as a Senior Advisor in Clinical Development Innovation at Lilly, focusing on developing and implementing innovative patient engagement solutions. He has spent over 15 years in the Pharma industry utilizing a unique approach that integrates his experiences working for Sponsors such as Shire and Merck, CROs, and technology vendors.
Joseph has a robust combination of experience that includes early and late phase clinical research, and a well known history of innovation in the clinical research industry, recognized as one of “20 Innovators Changing the Face of the Clinical Trials Industry” by CenterWatch in 2013. He holds a BS in Molecular Biology from Lehigh University and an MBA from Villanova. He can be reached at firstname.lastname@example.org and on Twitter.
Tell us a little bit about yourself and how you got started in clinical research.
For starters, you should know that I did not come to clinical research through any natural career path. In fact, I had two other careers as a social worker and high school science teacher before landing in clinical research. My first role was as an entry level data manager. Quite comfortable with trying things on and pivoting quickly, my instinct was, “This isn’t for me either.” Given that I worked for a large pharma company (Merck), I was able to quickly learn about other roles and try them on too. My next move was as a garden variety study manager in psychiatric research. This was the old model, where it was you and a medical monitor doing everything from writing the protocol, to selecting sites, to reviewing data, to paying grants.
Advances in computational science and biology enable us to understand ourselves in ways that we could not just a few years ago. Co-founded in 2006 by Anne Wojcicki, wife of Google co-founder Sergey Brin, 23andMe has emerged in the digital age to provide a view of our personal genetics – all for less than $100!
23andMe is evidence of Moore’s Law at work, and, in addition to giving unprecedented insight into our personal genome, efforts like 23andMe have innovative potential to change the way drugs are found and developed.
Thanks to Moore’s law, the cost per Human Genome is falling rapidly. More…
Regina Holliday’s husband Fred died of kidney cancer on June 17, 2009. His untimely death was a tragedy, but it served to reveal a gap in today’s healthcare landscape: patients’ access to their own medical data.
Telling her story, Regina recounts a lack of communication from Fred’s doctors and significant roadblocks to crucial information about both his history and the state of the cancer. Not long after his diagnosis, Regina lost her husband. But in that, she embraced a mission – and started a movement.
“The Walking Gallery” is a big part of that movement. It refers to striking, full-color mural scenes Regina has depicted in acrylic paint on the backs of suit jackets and lab-coats. The painted garments tell myriad stories: from patients’ struggles to health care enigmas, to reform ideas for national and global issues. They are worn to conferences and events by a variety of health advocates and friends of the movement.
Regina’s message is that without patients’ unique stories and perspectives, information that the public receives about disease, treatment options, and the whole of patient care is incomplete. More…